Association between chronic kidney disease and mortality in stage IV cancer

Ishii, Takefumi; Fujimaru, Takuya; Nakano, Eriko; Takahashi, Osamu; Nakayama, Masaaki; Yamauchi, Teruo; Komatsu, Yasuhiro

doi:10.1007/s10147-020-01715-9

Cited by 14 publications

(18 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To our knowledge, this is the first study to compare eGFRcr, eGFRcys and eGFRcr-cys for cancer risk. In contrast to studies that assessed the association between eGFRcr[ 3 , 5 , [7] , [8] , [9] , [10] , [11] , 27 ] or eGFRcr-cys [4] with cancer incidence and death, we have shown that eGFRcys 60–89 ml/min/1.73m 2 is associated with small but significant increases in cancer incidence, and a more pronounced association with cancer death.…”

Section: Discussioncontrasting

confidence: 99%

“…A more consistent association is observed between CKD and cancers of the urinary tract [ 1 , 3 , [7] , [8] , [9] , 29 ], which share common risk factors, such as the metabolic syndrome, smoking, prior nephrectomy, genetic conditions (such as tuberous sclerosis), occupational exposures and use of medications. Acute kidney injury (AKI) is known to contribute to CKD development [30] and is more likely to occur in those with CKD.…”

Section: Discussionmentioning

confidence: 99%

“…As kidney function, defined by estimated glomerular filtration rate (eGFR), falls below 60 ml/min/1.73m 2 , there is a well described increased risk of cardiovascular disease [2] but this is less clear for cancer risk. Several studies have demonstrated a potential association between markers of CKD (below eGFR 60 ml/min/1.73m 2 , alone or in combination with albuminuria) with higher risk of incidence and death from overall [3] , [4] , [5] , [6] and site-specific urinary [ 3 , [7] , [8] , [9] ], lung [3] and haematological [10] cancers. However, the data are inconsistent [ 1 , 4 , 7 , 11 ], possibly as most studies have assessed associations with eGFR calculated from serum creatinine [ 1 , 3 , 5 , [7] , [8] , [9] , [10] , [11] , [12] ], which has been shown to have a U-shaped relationship with cancer risk [12] .…”

Section: Introductionmentioning

confidence: 99%

“…Several studies have demonstrated a potential association between markers of CKD (below eGFR 60 ml/min/1.73m 2 , alone or in combination with albuminuria) with higher risk of incidence and death from overall [3] , [4] , [5] , [6] and site-specific urinary [ 3 , [7] , [8] , [9] ], lung [3] and haematological [10] cancers. However, the data are inconsistent [ 1 , 4 , 7 , 11 ], possibly as most studies have assessed associations with eGFR calculated from serum creatinine [ 1 , 3 , 5 , [7] , [8] , [9] , [10] , [11] , [12] ], which has been shown to have a U-shaped relationship with cancer risk [12] . Independent of the effect of eGFR and diabetes, albuminuria has been associated with higher risk of cancer overall [ 4 , 5 , 13 ], and particularly site-specific lung [ 4 , 5 , 13 , 14 ] and urinary tract [ 4 , 14 ] cancers.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Kidney function and cancer risk: An analysis using creatinine and cystatin C in a cohort study

Lees

Parra‐Soto

et al. 2021

eClinicalMedicine

View full text Add to dashboard Cite

Background: We examined whether an increased risk of cancer incidence and death is associated with kidney function and albuminuria and whether the risk is more readily identified when kidney function is estimated using cystatin C. Methods: Participants were from UK Biobank (recruitment spanning 2007À2010), excluding those with a prior diagnosis of cancer. Estimated glomerular filtration rate (ml/min/1.73m 2 ) was calculated using creatinine (eGFRcr), cystatin C (eGFRcys) and creatinine-cystatin C (eGFRcr-cys). Cox proportional hazards models tested associations between eGFR, urinary albumin:creatinine ratio (uACR) and cancer incidence and death. Findings: In 431,263 participants over median follow-up of 11.3 (IQR 10.6À12.0) years, there were 41,745 incident cancers and 11,764 cancer deaths. eGFRcys was most strongly associated with cancer incidence and death (HR 1.04 (95% CI 1.03À1.04) and 1.06 (1.05À1.07) per 10 ml/min/1.73m 2 decline, respectively). eGFRcr was not associated with either outcome (incidence: HR 1.00 (1.00À1.01); death: HR 0.99 (0.98À1.01) per 10 ml/min/1.73m 2 decline). Relative to eGFRcys>90 or uACR<3 mg/mmol, eGFRcys60À89 (HR 1.04 (95% CI 1.02À1.07)), eGFRcys<60 (HR 1.19 (1.14À1.24)) and uACR3 mg/mmol (HR 1.09 (1.06À1.12)) were associated with higher risk of incident cancer. eGFRcys60À89 (HR 1.15 (1.10À1.21)); eGFRcys<60 (HR 1.48 (1.38À1.59)) and uACR3 mg/mmol (HR 1.17 (1.11À1.24)) were associated with cancer death. Interpretation: Excess risk of cancer incidence and cancer death is more readily captured in early chronic kidney disease by eGFRcys than by current measures. The association between kidney function, uACR and cancer death in particular is concerning and warrants further scrutiny.

show abstract

Section: Discussioncontrasting

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Kidney function and cancer risk: An analysis using creatinine and cystatin C in a cohort study

Lees

Parra‐Soto

et al. 2021

eClinicalMedicine

View full text Add to dashboard Cite

show abstract

“…The vast majority of studies report cancer risk using eGFR based on serum creatinine alone (eGFRcr) (1)(2)(3)(4)(5)(6)(7)(8)(9)(10)(11). However, eGFR based on a combination of creatinine and cystatin C (eGFRcr-cys) has been shown to be more accurate than eGFRcr in comparison to measured GFR (12).…”

Section: Incident Cancer -Which Egfr Equation?mentioning

confidence: 99%

The ‘other’ big complication: how chronic kidney disease impacts on cancer risks and outcomes

Lees

Elyan

Herrmann

et al. 2022

Nephrology Dialysis Transplantation

View full text Add to dashboard Cite

Cancer is the second leading cause of death in people with chronic kidney disease (CKD) after cardiovascular disease. The incidence of CKD in patients with cancer is higher than in the non-cancer population. Across various populations, CKD is associated with an elevated risk of cancer incidence and cancer death compared to people without CKD, though the risks are cancer site-specific. Higher risk of cancer is detectable in mild CKD (estimated glomerular filtration rate [eGFR] 60–89 ml/min/1.73 m2) although this risk is more obvious if sensitive markers of kidney disease are used, such as cystatin C. Independent of eGFR, albuminuria is associated with increased risk of site-specific cancer incidence and death. Here, we explore the potential mechanisms for the increased risk of cancer observed in CKD, including patient factors (shared risks such as cardiometabolic disease, obesity, smoking, diet, lifestyle and environment), disease (genetic, inflammatory and infective) and treatment factors. In particular, we discuss the ways in which renal adverse events associated with conventional chemotherapies and newer systemic anti-cancer therapies (including targeted and immunotherapies) may contribute to worse cancer outcomes in people with CKD. Finally, we review the potential benefits of acknowledging increased risk of cancer in risk prediction tools used for management of CKD.

show abstract

Chapter 1: Evaluation of kidney function in patients undergoing anticancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022

et al. 2023

View full text Add to dashboard Cite

Association between chronic kidney disease and mortality in stage IV cancer

Cited by 14 publications

References 40 publications

Kidney function and cancer risk: An analysis using creatinine and cystatin C in a cohort study

Kidney function and cancer risk: An analysis using creatinine and cystatin C in a cohort study

The ‘other’ big complication: how chronic kidney disease impacts on cancer risks and outcomes

Chapter 1: Evaluation of kidney function in patients undergoing anticancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022

Contact Info

Product

Resources

About